European Archives - Page 66 of 1208 - European Medical Journal

EULAR 2025: Single-Cell Study Reveals Pro-Inflammatory Fibroblast Signature in Very Early Systemic Sclerosis

A new study from EULAR 2025 shows that patients with very early systemic sclerosis have a distinct pro-inflammatory fibroblast profile before any signs of fibrosis appear.

EAACI 2025: Chronic Urticaria Linked to Higher Rates of Comorbid Diseases

Conducted across 19 countries, this large-scale observational study gathered data from 1,392 patients with CSU and 1,374 healthy controls.

Onradivir Rivals Oseltamivir in Treating Influenza A

A large Phase III trial has found that onradivir, a novel PB2 polymerase inhibitor, significantly shortens recovery time in adults with uncomplicated influenza A.

Ultrasound Enhances Diagnosis of Forearm Lacerations in Trauma Care

High-resolution ultrasound improves diagnosis of tendon and nerve injuries in forearm lacerations, supporting better trauma care outcomes.

Breaking Barriers in Lung Cancer: Leveraging AI and Big Data in Clinical Care

In this second episode of our lung cancer miniseries, Jonathan Sackier is joined by David Baldwin, a leading expert in screening, epidemiology, and policy.

Dapagliflozin Emerges as Potential MASH Therapy in Landmark Study

Dapagliflozin shows promise for treating MASH, improving liver outcomes without worsening fibrosis in a major trial.

Showcasing Becker muscular dystrophy

Podcast series on Becker Muscular Dystrophy (BMD), exploring diagnosis, disease progression, treatment and…

Tackling Silent Liver Disease: A Global Health Priority

A 2023 global call to action by over 300 experts highlighted the need for clear, cross-specialty care pathways to support earlier identification and referral of people at risk.

UK clinical trial diversity needs work, finds ABPI

New Ipsos data shows that while 58% of UK adults are willing to join clinical trials, this drops to 41% among ethnic minority adults.

EULAR 2025: MONITOR-PsA Study Confirms Feasibility of Treat-to-Target in Routine Practice

A new analysis from the MONITOR-PsA study, presented at EULAR 2025, demonstrates that a pragmatic treat-to-target (T2T) approach in psoriatic arthritis leads to promising clinical outcomes over 48 weeks.